Innate Pharma S.A. (IPHYF) has a profit margin of -995.3%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Innate Pharma S.A. (IPHYF) currently reports a profit margin of -995.3% as of June 2026. That compares with -97.66% in the prior-year period — down 919.2% year over year. That is below the Healthcare sector average of 17.63%. Use the charts on this page to explore Innate Pharma S.A.'s profit margin history and peer comparisons.
Innate Pharma S.A.'s profit margin decreased from -97.66% to -995.3% — a 919.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Innate Pharma S.A.'s profit margin of -995.3% is lower than the Healthcare sector average of 17.63%. That is roughly 5746.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Innate Pharma S.A.'s current -995.3% should be judged against Healthcare norms (sector average: 17.63%) and against IPHYF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -995.3%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for Innate Pharma S.A., and consider following IPHYF for alerts when major investors trade the stock.